- Home
- DBD vs BCRX Comparison
DBD vs BCRX Comparison
Compare DBD & BCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBD
- BCRX
- Stock Information
- Founded
- DBD 1859
- BCRX 1986
- Country
- DBD United States
- BCRX United States
- Employees
- DBD N/A
- BCRX N/A
- Industry
- DBD EDP Services
- BCRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DBD Technology
- BCRX Health Care
- Exchange
- DBD Nasdaq
- BCRX Nasdaq
- Market Cap
- DBD 1.9B
- BCRX 1.7B
- IPO Year
- DBD N/A
- BCRX 1994
- Fundamental
- Price
- DBD $59.00
- BCRX $8.93
- Analyst Decision
- DBD Strong Buy
- BCRX Strong Buy
- Analyst Count
- DBD 2
- BCRX 10
- Target Price
- DBD $65.00
- BCRX $16.70
- AVG Volume (30 Days)
- DBD 287.1K
- BCRX 3.5M
- Earning Date
- DBD 08-06-2025
- BCRX 08-04-2025
- Dividend Yield
- DBD N/A
- BCRX N/A
- EPS Growth
- DBD N/A
- BCRX N/A
- EPS
- DBD N/A
- BCRX N/A
- Revenue
- DBD $3,696,800,000.00
- BCRX $503,485,000.00
- Revenue This Year
- DBD $2.02
- BCRX $39.04
- Revenue Next Year
- DBD $1.96
- BCRX $13.26
- P/E Ratio
- DBD N/A
- BCRX N/A
- Revenue Growth
- DBD N/A
- BCRX 41.67
- 52 Week Low
- DBD $34.38
- BCRX $6.02
- 52 Week High
- DBD $59.31
- BCRX $11.31
- Technical
- Relative Strength Index (RSI)
- DBD 84.37
- BCRX 30.04
- Support Level
- DBD $55.26
- BCRX $8.89
- Resistance Level
- DBD $52.30
- BCRX $9.17
- Average True Range (ATR)
- DBD 1.04
- BCRX 0.34
- MACD
- DBD 0.46
- BCRX -0.18
- Stochastic Oscillator
- DBD 96.03
- BCRX 4.43
About DBD Diebold Nixdorf Incorporated Common stock
Diebold Nixdorf Inc is engaged in providing software and hardware services for financial and retail industries. The customer segments of the company are Banking, which offers integrated solutions for financial institutions, and Retail, which offers solutions, software, and services that improve the checkout process for retailers. A majority of its revenue is generated from the Banking segment. Geographically, the company generates maximum revenue from Europe, Middle East, and Africa (EMEA), followed by the Americas and the Asia-Pacific region.
About BCRX BioCryst Pharmaceuticals Inc.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.